Glenmark Pharmaceuticals Inc., USA announced the upcoming launch of its generic Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials in September 2025, marking a significant milestone as the company's first complex generic product. The generic formulation is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven® Injection from Eisai, Inc.
Market Impact and Financial Opportunity
According to IQVIA® sales data for the 12-month period ending July 2025, the Halaven® Injection market achieved annual sales of approximately $66.3 million. This substantial market size underscores the commercial potential for Glenmark's generic entry, which aims to provide more affordable treatment options for patients requiring eribulin mesylate therapy.
Strategic Significance for Glenmark
Marc Kikuchi, President & Business Head, North America, emphasized the strategic importance of this launch: "We are pleased to announce the launch of Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials. As the first complex generic in our portfolio, this launch marks both our commitment to growing our portfolio of products within the institutional channel and reinforces our dedication to bring quality and affordable alternatives to market for patients in need."
The launch represents Glenmark's expansion into complex generic formulations, demonstrating the company's manufacturing capabilities and regulatory expertise in developing challenging-to-manufacture pharmaceutical products.
Company Profile and Market Position
Glenmark Pharmaceuticals Ltd. operates as a research-led, global pharmaceutical company with presence across Branded, Generics, and OTC segments, focusing on therapeutic areas of respiratory, dermatology and oncology. The company maintains 11 world-class manufacturing facilities across 4 continents and operations in over 80 countries.
The company's market recognition includes positioning among the Top 100 biopharmaceutical companies ranked by Pharmaceutical Sales in 2023 according to Scrip 100, and placement in the Top 50 Generics and biosimilar companies ranked by sales in 2024 by Generics Bulletin. Additionally, Glenmark's Green House Gas emission reduction targets received approval in 2023 by the Science Based Target initiative, making it only the second pharmaceutical company in India to achieve this recognition.
